Genscript Biotech 

€1.4
0
-€0.08-5.41% Today

Statistics

Day High
1.43
Day Low
1.4
52W High
2.04
52W Low
1.13
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Jun 17
€0
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

15MarExpected
Q4 2025
-0.2
-0.14
-0.08
-0.03
Expected EPS
-0.026244899999999998
Actual EPS
-0.2012109

People Also Follow

This list is based on the watchlists of people on Stock Events who follow G51.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap20.63B
Illumina provides genomic sequencing solutions and competes in the biotechnology tools space, similar to Genscript's offerings in genomics and proteomics.
Thermo Fisher Scientific
TMO
Mkt Cap174.37B
Thermo Fisher Scientific offers a range of biotechnology products, including gene synthesis and editing tools, directly competing with Genscript's biotech services.
Qiagen NV
QGEN
Mkt Cap7.06B
Qiagen is a major player in providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, overlapping with Genscript's molecular biology products.
Bio-Rad Laboratories
BIO
Mkt Cap6.93B
Bio-Rad Laboratories manufactures and supplies products and systems used for gene expression, competing in the same biotech instrumentation sector as Genscript.
Pacific Biosciences of California
PACB
Mkt Cap496.78M
Pacific Biosciences offers genomic analysis systems, which compete with Genscript's services in the genomics field.
Intellia Therapeutics
NTLA
Mkt Cap1.58B
Intellia Therapeutics is a leading developer of CRISPR gene editing technology, a direct competitor to Genscript's CRISPR-based product offerings.
Editas Medicine
EDIT
Mkt Cap283.93M
Editas Medicine is involved in gene editing technology, particularly CRISPR, which is a growing area of competition for Genscript's gene and cell therapy services.
Sangamo Therapeutics
SGMO
Mkt Cap55.93M
Sangamo Therapeutics focuses on genomic medicine, including gene editing, competing with Genscript's genomic and genetic engineering technologies.
Twist Bioscience
TWST
Mkt Cap3.7B
Twist Bioscience operates in the synthetic biology field, providing synthetic DNA tools that are competitive with Genscript's gene synthesis services.
CRISPR Therapeutics
CRSP
Mkt Cap4.98B
CRISPR Therapeutics is focused on the development of gene-based medicines using CRISPR/Cas9 technology, competing with Genscript's similar technological applications in gene therapy.

About

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Science Services and Products segment provide research services and products which are used in fundamental to life-science research and application. The Biologics Development Services segment which helps biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment develops and produces industrial enzymes through non-pathogenic microbial strains constructed using genetic engineering. It also offers SurePAGE, a precast gel series; CytoSinct, a Nanobeads product and services; and Benz-Neburase, a genetically engineered endonuclease. In addition, the company provides automated protein and antibody purification system; automated maxi-plasmid purification; automated mini-scale purification for plasmid, protein, and antibody; eBlot and eStain, a protein transfer and staining system; eZwest Lite, an automated western blotting device; CytoSinct, a cell isolation solution; pharmacokinetics and immunogenicity ELISA kits; COVID-19 detection cPass technology kits; and GenBox, a mini electrophoresis tank. It serves antibody drug discovery; gene therapy; vaccine; in vitro diagnostics; gene editing; plant biology; and synthetic biology solutions. The company was founded in 2002 and is headquartered in Wan Chai, Hong Kong.
Show more...
CEO
ISIN
KYG3825B1059

Listings

0 Comments

Share your thoughts

FAQ

What is Genscript Biotech stock price today?
The current price of G51.STU is €1.4 EUR — it has decreased by -5.41% in the past 24 hours. Watch Genscript Biotech stock price performance more closely on the chart.
What is Genscript Biotech stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Genscript Biotech stocks are traded under the ticker G51.STU.
Is Genscript Biotech stock price growing?
G51.STU stock has fallen by -2.78% compared to the previous week, the month change is a +5.82% rise, over the last year Genscript Biotech has showed a +11.91% increase.
When is the next Genscript Biotech earnings date?
Genscript Biotech is going to release the next earnings report on August 17, 2026.
What were Genscript Biotech earnings last quarter?
G51.STU earnings for the last quarter are -0.2 EUR per share, whereas the estimation was -0.03 EUR resulting in a -666.67% surprise. The estimated earnings for the next quarter are N/A EUR per share.
Does Genscript Biotech pay dividends?
Yes, G51.STU dividends are paid annual. The last dividend per share was 0 EUR. As of today, Dividend Yield (FWD)% is 0%.
In which sector is Genscript Biotech located?
Genscript Biotech operates in the Other sector.
When did Genscript Biotech complete a stock split?
Genscript Biotech has not had any recent stock splits.